{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:46:05Z","timestamp":1793418365694,"version":"4.5.0"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with &amp;gt;70-fold selecti\u00advity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non\u2013small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I\/II study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the \u223c10% of patients with cancer with this biomarker.<\/jats:p>\n                    <jats:p>See related commentary by Mulvaney, p. 2310.<\/jats:p>\n                    <jats:p>This article is featured in Selected Articles from This Issue, p. 2293<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-23-0669","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T16:11:06Z","timestamp":1691511066000},"page":"2412-2431","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":240,"title":["MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with\n                    <i>MTAP<\/i>\n                    -Deleted Cancer"],"prefix":"10.1158","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-9427","authenticated-orcid":false,"given":"Lars D.","family":"Engstrom","sequence":"first","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1754-7367","authenticated-orcid":false,"given":"Ruth","family":"Aranda","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0127-1631","authenticated-orcid":false,"given":"Laura","family":"Waters","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6717-8934","authenticated-orcid":false,"given":"Krystal","family":"Moya","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-9225","authenticated-orcid":false,"given":"Vickie","family":"Bowcut","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9860-746X","authenticated-orcid":false,"given":"Laura","family":"Vegar","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7534-1430","authenticated-orcid":false,"given":"David","family":"Trinh","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0766-2386","authenticated-orcid":false,"given":"Allan","family":"Hebbert","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-2791","authenticated-orcid":false,"given":"Christopher R.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0346-3441","authenticated-orcid":false,"given":"Svitlana","family":"Kulyk","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5232-4539","authenticated-orcid":false,"given":"J. David","family":"Lawson","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2732-2486","authenticated-orcid":false,"given":"Leo","family":"He","sequence":"additional","affiliation":[{"name":"2Monoceros Biosciences LLC, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2106-8679","authenticated-orcid":false,"given":"Laura D.","family":"Hover","sequence":"additional","affiliation":[{"name":"2Monoceros Biosciences LLC, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-1286","authenticated-orcid":false,"given":"Julio","family":"Fernandez-Banet","sequence":"additional","affiliation":[{"name":"2Monoceros Biosciences LLC, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-7116","authenticated-orcid":false,"given":"Jill","family":"Hallin","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9941-0240","authenticated-orcid":false,"given":"Darin","family":"Vanderpool","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3868-0859","authenticated-orcid":false,"given":"David M.","family":"Briere","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2498-7343","authenticated-orcid":false,"given":"Alice","family":"Blaj","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2351-4787","authenticated-orcid":false,"given":"Matthew A.","family":"Marx","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[{"name":"3Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3018","authenticated-orcid":false,"given":"Michael","family":"Offin","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Division of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-8427","authenticated-orcid":false,"given":"Kathryn C.","family":"Arbour","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Division of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-1314","authenticated-orcid":false,"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"5Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-5219","authenticated-orcid":false,"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"7Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7821-4928","authenticated-orcid":false,"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[{"name":"6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"7Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-0632","authenticated-orcid":false,"given":"Candace L.","family":"Haddox","sequence":"additional","affiliation":[{"name":"6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-2620","authenticated-orcid":false,"given":"Kyriakos P.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"8South Texas Accelerated Research Therapeutics, San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-4227","authenticated-orcid":false,"given":"Jason T.","family":"Henry","sequence":"additional","affiliation":[{"name":"9Sarah Cannon Research Institute at HealthOne, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9784-8603","authenticated-orcid":false,"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[{"name":"10Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-0335","authenticated-orcid":false,"given":"James G.","family":"Christensen","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0231-3436","authenticated-orcid":false,"given":"Ronald","family":"Shazer","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5164-8102","authenticated-orcid":false,"given":"Peter","family":"Olson","sequence":"additional","affiliation":[{"name":"1Mirati Therapeutics, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"2023110107493771200_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"19","author":"Huang","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2023110107493771200_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.trecan.2015.10.002","article-title":"Collateral lethality: a new therapeutic strategy in oncology","volume":"1","author":"Muller","year":"2015","journal-title":"Trends Cancer"},{"key":"2023110107493771200_bib3","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/bjc.2013.7","article-title":"Common genetic variants in the 9p21 region and their associations with multiple tumours","volume":"108","author":"Gu","year":"2013","journal-title":"Br J Cancer"},{"key":"2023110107493771200_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol Cell"},{"key":"2023110107493771200_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"key":"2023110107493771200_bib6","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.molcel.2021.07.019","article-title":"Molecular basis for substrate recruitment to the PRMT5 methylosome","volume":"81","author":"Mulvaney","year":"2021","journal-title":"Mol Cell"},{"key":"2023110107493771200_bib7","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"2023110107493771200_bib8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"key":"2023110107493771200_bib9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"2023110107493771200_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0969-2126(99)80084-7","article-title":"The structure of human 5\u2032-deoxy-5\u2032-methylthioadenosine phosphorylase at 1.7 A resolution provides insights into substrate binding and catalysis","volume":"7","author":"Appleby","year":"1999","journal-title":"Structure"},{"key":"2023110107493771200_bib11","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small molecule inhibitor of PRMT5 with potent anti-tumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2023110107493771200_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat Chem Biol"},{"key":"2023110107493771200_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: a review","volume":"5","author":"Feustel","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"2023110107493771200_bib14","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2023110107493771200_bib15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-based discovery of MRTX1719, a synthetic lethal inhibi\u00adtor of the PRMT5*MTA complex for the treatment of MTAP-deleted cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J Med Chem"},{"key":"2023110107493771200_bib16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1083\/jcb.200207028","article-title":"Symmetrical dimethylarginine methylation is required for the localization of SMN in Cajal bodies and pre-mRNA splicing","volume":"159","author":"Boisvert","year":"2002","journal-title":"J Cell Biol"},{"key":"2023110107493771200_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1017\/S135583820101442X","article-title":"Symmetrical dimethylation of arginine residues in spliceosomal Sm protein B\/B\u2019 and the Sm-like protein LSm4, and their interaction with the SMN protein","volume":"7","author":"Brahms","year":"2001","journal-title":"RNA"},{"key":"2023110107493771200_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.08.018","article-title":"Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma","volume":"32","author":"Braun","year":"2017","journal-title":"Cancer Cell"},{"key":"2023110107493771200_bib19","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","article-title":"PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell Rep"},{"key":"2023110107493771200_bib20","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci Rep"},{"key":"2023110107493771200_bib21","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1038\/s41467-021-24240-3","article-title":"Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine","volume":"12","author":"Barekatain","year":"2021","journal-title":"Nat Commun"},{"key":"2023110107493771200_bib22","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-0220","article-title":"Keyboard: a novel Bayesian toxicity probability interval design for phase I clinical trials","volume":"23","author":"Yan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023110107493771200_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2023110107493771200_bib24","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1172\/JCI81749","article-title":"Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis","volume":"125","author":"Liu","year":"2015","journal-title":"J Clin Invest"},{"key":"2023110107493771200_bib25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nsmb.1568","article-title":"PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing","volume":"16","author":"Zhao","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"2023110107493771200_bib26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1101\/gr.213611.116","article-title":"Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly","volume":"27","author":"Schneider","year":"2017","journal-title":"Genome Res"},{"key":"2023110107493771200_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2023110107493771200_bib28","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2023110107493771200_bib29","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023110107493771200_bib30","doi-asserted-by":"crossref","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","article-title":"rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-seq data","volume":"111","author":"Shen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-23-0669\/3355023\/cd-23-0669.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-23-0669\/3370491\/cd-23-0669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/13\/11\/2412\/3378595\/2412.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/13\/11\/2412\/3378595\/2412.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T04:27:00Z","timestamp":1698812820000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/13\/11\/2412\/729848\/MRTX1719-Is-an-MTA-Cooperative-PRMT5-Inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,8,8]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-23-0669","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.27026177","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026189","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026174.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026165","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474131.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474131","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026171.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026177.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026159.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474116.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474119.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474116","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474104","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474101.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474128","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474140","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026186","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026162","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026174","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474110.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026162.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026156.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474137.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474137","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474125","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474122.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474128.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026159","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474125.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026168.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026165.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474101","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026171","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026183","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026180.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474140.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026186.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026183.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474107.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026189.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474104.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026168","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026156","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474122","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474110","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27026180","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474119","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24474107","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6908522.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6908522","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}